S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Behind the tech boom: Big price leaders selectively laying off
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Behind the tech boom: Big price leaders selectively laying off
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Behind the tech boom: Big price leaders selectively laying off
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Behind the tech boom: Big price leaders selectively laying off
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases

Inhibrx Stock Price, News & Analysis (NASDAQ:INBX)

$22.39
+1.62 (+7.80%)
(As of 12/1/2023 ET)
Compare
Today's Range
$19.86
$22.44
50-Day Range
$14.50
$22.39
52-Week Range
$14.31
$32.71
Volume
277,479 shs
Average Volume
400,877 shs
Market Capitalization
$1.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.50

Inhibrx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
63.0% Upside
$36.50 Price Target
Short Interest
Bearish
15.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.21
Upright™ Environmental Score
News Sentiment
0.44mentions of Inhibrx in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.45) to ($4.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

453rd out of 954 stocks

Biological Products, Except Diagnostic Industry

75th out of 159 stocks


INBX stock logo

About Inhibrx Stock (NASDAQ:INBX)

Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.

INBX Stock Price History

INBX Stock News Headlines

Inhibrx posts Q3 results
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
JMP Securities Reaffirms Their Buy Rating on Inhibrx (INBX)
LifeSci Capital Sticks to Their Buy Rating for Inhibrx (INBX)
Inhibrx: Undercovered Company With Good Potential
See More Headlines
Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/04/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INBX
Fax
N/A
Employees
132
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.50
High Stock Price Target
$46.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+63.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-145,230,000.00
Net Margins
-42,880.00%
Pretax Margin
-42,878.64%

Debt

Sales & Book Value

Annual Sales
$2.19 million
Book Value
$2.74 per share

Miscellaneous

Free Float
36,792,000
Market Cap
$1.06 billion
Optionable
Not Optionable
Beta
2.72
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives















INBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Inhibrx stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INBX shares.
View INBX analyst ratings
or view top-rated stocks.

What is Inhibrx's stock price target for 2024?

3 Wall Street research analysts have issued twelve-month price targets for Inhibrx's shares. Their INBX share price targets range from $27.00 to $46.00. On average, they expect the company's share price to reach $36.50 in the next twelve months. This suggests a possible upside of 63.0% from the stock's current price.
View analysts price targets for INBX
or view top-rated stocks among Wall Street analysts.

How have INBX shares performed in 2023?

Inhibrx's stock was trading at $24.64 on January 1st, 2023. Since then, INBX shares have decreased by 9.1% and is now trading at $22.39.
View the best growth stocks for 2023 here
.

Are investors shorting Inhibrx?

Inhibrx saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 5,290,000 shares, an increase of 5.4% from the October 31st total of 5,020,000 shares. Based on an average daily trading volume, of 441,300 shares, the days-to-cover ratio is presently 12.0 days. Currently, 15.3% of the shares of the stock are sold short.
View Inhibrx's Short Interest
.

When is Inhibrx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our INBX earnings forecast
.

How were Inhibrx's earnings last quarter?

Inhibrx, Inc. (NASDAQ:INBX) released its earnings results on Thursday, November, 9th. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by $0.09. The company earned $0.12 million during the quarter. Inhibrx had a negative net margin of 42,880.00% and a negative trailing twelve-month return on equity of 424.05%.

What other stocks do shareholders of Inhibrx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU).

When did Inhibrx IPO?

(INBX) raised $102 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are Inhibrx's major shareholders?

Inhibrx's stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.99%), FMR LLC (3.48%), Loomis Sayles & Co. L P (2.56%), Eventide Asset Management LLC (0.99%), Northern Trust Corp (0.72%) and Schroder Investment Management Group (0.50%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe.
View institutional ownership trends
.

How do I buy shares of Inhibrx?

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:INBX) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -